Zydus Ties Up With Synthon for MS Drug in US
ECONOMY & POLICY

Zydus Ties Up With Synthon for MS Drug in US

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).
The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.
As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.
The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.
This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Next Story
Infrastructure Urban

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Next Story
Equipment

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Next Story
Equipment

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement